MINDACT in the News

News, videos, social media and more about the recently released MINDACT phase III, prospective randomized trial results  The primary analysis from the MINDACT clinical trial was presented by Martine Piccart, MD, PhD at the American Association for Cancer Research (AACR) annual meeting … Continued

Agendia Appoints Dr. M. William Audeh to Chief Medical Officer

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, recently announced the appointment of veteran medical oncologist M. William Audeh, MD, MS to the position of Chief Medical Officer. “I’m very pleased … Continued

Agendia’s MammaPrint® First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients

Clinical high-risk patients with a low-risk MammaPrint® result, including 48 percent node-positive, had five-year distant metastasis-free survival rate in excess of 94 percent, whether randomized to receive adjuvant chemotherapy or not MammaPrint could change clinical practice by substantially de-escalating the … Continued